ClinicalTrials.gg
Not yet recruitingNCT07615660CVL006-T1003Updated May 29, 2026

Clinical Study of CVL006 Combination With 9MW2821

A Phase 1/2 interventional study of CVL006 in combination with 9MW2821 and CVL006 in combination with 9MW2821 in Advanced Solid Tumor, sponsored by Convalife (Shanghai) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Convalife (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with 9MW821 patients with advanced solid tumors.

Read the detailed description

In this Phase Ib study, dose escalation of CVLL006 combined with 9MW2821 (at a fixed dose) will be conducted using a 3+3 design:

Initially, 3 study participants will be enrolled into the starting dose level for DLT observation.

If no DLT occurs in all 3 participants after completion of the DLT observation period, dose escalation to the next dose level may proceed.

If 1 out of the 3 participants experiences a DLT, an additional 3 participants will be enrolled.

If no DLT is observed in the additional 3 participants, dose escalation to the next dose level may proceed.

If a DLT occurs in any of the additional 3 participants, dose escalation will be terminated.

If ≥2 out of the initial 3 participants experience DLTs, dose escalation will be terminated immediately.

Under normal circumstances, each study participant will receive study drug from only one dose level, and intra-individual dose escalation is not permitted.

The addition of new dosing schedules and dose levels will be determined through discussion between the investigator and the sponsor, based on available study data including safety, tolerability, pharmacokinetic (PK), and efficacy profiles.

If a participant fails to complete the DLT observation period for reasons other than DLT (including but not limited to withdrawal from the study during the DLT observation period), a replacement participant may be enrolled.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Advanced Solid Tumor
  • Combination medication
  • DLT
  • RP2D
03

In context

Lead sponsor

Convalife (Shanghai) Co., Ltd. is the lead sponsor of 9 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-75 years old (inclusive), no restriction on gender.
  • Patients with or cytologically confirmed advanced solid tumors. Cohort A: Squamous cell carcinoma of the head and neck; the primary tumor must arise from the oral cavity, oropharynx, hypopharynx or larynx, excluding nasopharyngeal tumors, salivary gland tumors and/or parotid gland tumors.
  • For Phase Ib participants: Advanced solid tumors with failure of prior standard therapy. For Phase II part, Cohort A: Recurrent or disease not curable by local therapy. Participants must have no prior systemic therapy, unless the prior systemic therapy was completed more than 6 months ago as or neoadjuvant treatment. Participants who received prior /PD-L1 inhibitors in curative therapy are eligible if at least 12 months have elapsed since the last dose of anti-PD-L1 agent. Cohort B: No prior systemic therapy for locally advanced or metastatic disease. For patients who received adjuvant/neoadjuvant therapy or curative chemoradiotherapy, disease progression within 6 months after the last treatment is regarded as setting.
  • For Phase II: PD-L1 Combined Positive Score (CPS) ≥ 1 confirmed by local or central immunohistochemistry (IHC). If no PD-L1 testing result is available, participants shall submit archived or fresh tumor tissue samples during screening for central laboratory testing of programmed death ligand-1 (PD-L1) and Nectin4. The central PD-L1 testing result must be obtained prior to enrollment. Participants with known PD-L1 results confirming CPS ≥ 1 shall submit archived or fresh tissue samples for exploratory analysis within 5 days after enrollment.
  • (ECOG) performance status (PS): 0-1.
  • Estimated survival time ≥ 3 months.
  • At least one as defined by (RECIST 1.1).
  • Adequate bone marrow and organ function (no blood components and/or hematopoietic growth factors administered within 14 days prior to the initiation of study treatment):

(HB) ≥ 90 g/L; (ANC) ≥ 1.5×10⁹/L; (PLT) ≥ 90×10⁹/L; Total \< 1.5× (for participants with confirmed Gilbert's syndrome, total bilirubin ≤ 3×ULN); (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN; Serum creatinine ≤ 1.5×ULN or ≥ 60 mL/min (calculated by the Cockcroft-Gault formula); nternational Normalized Ratio () and activated partial thromboplastin time (APTT) ≤ 1.5×ULN;

  • Urinalysis protein ≤ 1+; or if urine protein ≥ 2+, 24-hour urine protein \< 1 g.
  • Females of must agree to abstain from heterosexual intercourse or use highly effective methods from the signing of until at least 6 months after the last dose of study drug. Serum HCG test must be negative within 7 days prior to study treatment initiation, and participants must be non-lactating. (A positive serum pregnancy test requires exclusion of pregnancy, and enrollment can only be confirmed after discussion with the sponsor.)
  • Male patients with female partners of childbearing potential must agree to abstain from intercourse or use highly effective contraceptive methods from the signing of informed consent until at least 6 months after the last dose of study drug. Male participants must also agree not to donate sperm during the same period.
  • Participants voluntarily join the study, sign the informed consent form, and have good treatment compliance.

Exclusion criteria

Exclusion Criteria:

  • 1. Participants with active central nervous system (CNS) are excluded. Participants with previously treated are eligible only if all of the following criteria are met: The CNS metastases have been clinically stable for ≥ 6 weeks prior to screening; If therapy is required for CNS metastases, participants are on a stable steroid dose equivalent to ≤ 20 mg/day prednisone for at least 2 weeks; Baseline imaging shows no evidence of new or enlarging brain metastases; Participants have no .
  • Participants with other malignant tumors within 5 years prior to the first dose of study drug, except adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, locally confined prostate cancer after radical resection, ductal carcinoma in situ after radical resection, and papillary thyroid carcinoma after radical resection.
  • Participants with tumors judged by the Investigator to be prone to bleeding, including those with imaging evidence of tumor invasion into or encasement of major blood vessels on screening imaging.
  • Participants with prior exposure to VEGF/ (PD-L1) bispecific antibodies or Nectin4-targeted therapy.
  • Participants with severe cardiovascular and cerebrovascular diseases, including but not limited to:

Severe cardiac rhythm or conduction abnormalities within 6 months prior to the first study drug dose, such as ventricular arrhythmias requiring clinical intervention, second- or third-degree atrioventricular block; History of acute coronary syndrome, congestive heart failure ( [NYHA] functional class ≥ II), or aortic dissection within 6 months prior to the first dose; History of arteriovenous thromboembolic events within 6 months prior to the first dose, such as cerebrovascular accident (, cerebral hemorrhage, stroke), deep vein thrombosis and pulmonary embolism; (LVEF) \< 50% within 28 days prior to the first dose; Mean interval averaged from 3 baseline 12-lead (or more) at rest: QTcF > 470 ms (female) or QTcF > 450 ms (male).

  • Participants with persistent toxicities (≥ Grade 2, alopecia excluded) related to prior therapy (including systemic therapy, radiotherapy or surgery). Participants with persistent ≥ Grade 2 immune-related hypothyroidism or panhypopituitarism are excluded. Participants with persistent immune-related colitis, uveitis, myocarditis, pneumonitis, or other immune-related adverse events requiring high-dose steroid therapy (> 20 mg/day prednisone or equivalent) are excluded. Participants with well-controlled ≤ Grade 2 immune-related hypothyroidism or panhypopituitarism on stable hormone replacement therapy (if applicable) are eligible. Participants with ≥ Grade 2 sensory or motor neuropathy are excluded.
  • Participants with active diseases or a history of autoimmune diseases prone to recurrence (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis), excluding clinically stable autoimmune thyroid disease and type 1 diabetes mellitus.
  • Participants who have undergone major surgery within 4 weeks prior to the first study drug dose; received radiotherapy, chemotherapy, biological agents, drugs, and/or immunotherapy for antitumor purposes within 2 weeks prior to the first dose; or received traditional Chinese medicine with antitumor indications within 2 weeks prior to the first dose.
  • Participants with a history of steroid-dependent (non-infectious) pneumonitis/interstitial lung disease or currently suffering from such diseases; history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonia; or evidence of active pneumonitis on chest CT during screening.
  • Participants judged by the Investigator to have an expected survival of less than 3 months and/or rapidly progressive disease (e.g., tumor bleeding, uncontrolled tumor pain).
  • Participants with a history of esophageal gastric varices, severe peptic ulcer, unhealed wounds, abdominal fistula, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months prior to the first dose; history of gastrointestinal perforation and/or fistula, severe gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), or extensive intestinal resection (partial colectomy or extensive small bowel resection) within 6 months prior to the first dose.
  • Participants with a history of immunodeficiency including positive test; active infection (HBV DNA above the of the local study center) or infection (anti-HCV positive and HCV RNA above the lower limit of quantification of the assay).
  • Participants with active pulmonary tuberculosis infection within 1 year prior to enrollment confirmed by medical history or CT examination; or those with a history of active pulmonary tuberculosis infection more than 1 year ago without standard anti-tuberculosis treatment.
  • Participants with a history of bleeding tendency or coagulation disorders and/or clinically significant bleeding symptoms or risks within 4 weeks prior to the first dose, including but not limited to:
  • a. Gastrointestinal bleeding;
  • b. Hemoptysis (coughing up ≥ 15 mL fresh blood or blood clots);
  • c. Epistaxis;
  • d. Receiving therapeutic anticoagulation prior to the first dose.
  • Participants with a history of hypertensive crisis or hypertensive encephalopathy; persistent hypertension within 1 month prior to the first dose with systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite oral antihypertensive treatment.
  • Participants with uncontrolled diabetes within 3 months prior to the first study treatment dose, defined as: (HbA1c) ≥ 8%; or HbA1c between 7% and \< 8% accompanied by unexplained diabetes-related symptoms (polyuria or polydipsia).
  • Participants with active or prior history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis or chronic diarrhea).
  • Participants with a known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  • Participants who have received within 30 days prior to the first dose or plan to receive live vaccines during the study period.
  • Participants with known active keratitis or corneal ulcer are excluded; participants with superficial punctate keratitis under adequate treatment are allowed to be enrolled.
  • Participants requiring use of strong inhibitors or inducers of cytochrome P450 3A4 () within 2 weeks prior to the first study dose and during the study period (concomitant use of strong CYP3A4 inhibitors or inducers is prohibited; representative drugs are listed in the appendix).
  • Participants with any other conditions judged by the Investigator that may interfere with study results or lead to premature study termination, such as alcohol abuse, drug abuse, uncontrolled severe diseases (including psychiatric disorders) requiring combined medication, significantly abnormal laboratory parameters, family/social factors, or any other conditions that may compromise participant safety or affect study data collection.
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Arm 1:

    Arm 1:CVL006 10 mg/kg +9MW2821 1.5mg/kg D1/D15 Q4W,

    Drug: CVL006 in combination with 9MW2821

  • Experimental
    Arm 2:

    Arm 2:CVL006 20 mg/kg +9MW2821 1.5mg/kg D1/D15 Q4W,

    Drug: CVL006 in combination with 9MW2821

  • Experimental
    Arm3:

    Arm3: CVL006 20 mg/kg D1/D15 +9MW2821 1.25mg/kg D1/D8/D15 Q4W。

    Drug: CVL006 in combination with 9MW2821

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    DLT(Dose-Limiting Toxicity and RP2D( Recommended Phase 2 Dose)of phase I in patients with advanced solid tumors

    Time frame: From date of randomization until the date of first documented progression, assessed up to 36 months

Secondary outcomes

  1. Secondary Outcome Measure

    Efficacy endpoints for Phase I and Phase II: Evaluated by the investigators based on RECISTv1.1 criteria, including objective response rate (ORR)

    Time frame: From date of randomization until the date of first documented progression, assessed up to 36 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Apr 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 29, 2026
StartEst.
May 15, 2026
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2029
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07615660
Lead sponsor
Convalife (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
May 29, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
May 29, 2026

Study contacts

Qiong Wang
Contact
qiong.wang@convalife.com
(021)6877 3638
Chunhui Shi
Contact
chunhui.shi@convalife.com
(021)6877 3638

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CVL006 · Bulumtatug fuvedotin

Start the discussion